Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca AbfiledCriticalAstrazeneca Ab
Priority to CU20100004ApriorityCriticalpatent/CU20100004A7/en
Publication of CU20100004A7publicationCriticalpatent/CU20100004A7/en
Un compuesto de fórmula (I) ESPACIO PARA LA FÓRMULA o una sal farmacéuticamente aceptable del mismo, procesos para su preparación, composiciones farmacéuticas que los contienen y su uso en terapia, por ejemplo en el tratamiento de enfermedad proliferativa tal como cáncer y particularmente en una enfermedad mediada por una quinasa mTOR quinasa y/o una o más enzimas PI3K.A compound of formula (I) SPACE FOR FORMULA or a pharmaceutically acceptable salt thereof, processes for its preparation, pharmaceutical compositions containing them and their use in therapy, for example in the treatment of proliferative disease such as cancer and particularly in a mTOR kinase kinase-mediated disease and / or one or more PI3K enzymes.
CU20100004A2010-01-082010-01-08
PYRIMIDINE MORFOLINE DERIVATIVES USED IN DISEASES RELATED TO MTOR QUINASA AND / OR PI3K
CU20100004A7
(en)
"Substituted indazole-derived compounds, modulators of protein kinase activity; process of obtaining them; in vitro method to inhibit protein kinases; pharmaceutical composition and combination comprising them; and its use in the treatment of cancer "pct
Tricyclic compounds that inhibit the kinase pi3 (pi3k); pharmaceutical composition that includes them; method to treat cancer; and its use for the treatment of cancer.
Compounds derived from [1,2,4] triazolo [1,5-a] pyridine, jak2 or fak inhibitors; pharmaceutical compositions comprising them; and its use for the treatment of a hyperproliferative disease.